Klaria Pharma

Fourth quarter of 2023

Remaining business operations

- Net sales 0.0 MSEK (2.2 MSEK)

- Other income 0.2 MSEK (0.2 MSEK)

- R&D costs for the quarter amounted to 1.5 MSEK (8.6 MSEK)

- Profit after tax amounted to -7.9 MSEK (-12.9 MSEK)

- Earnings per share for the quarter amounted to -0.07 SEK (-0.22 SEK)

- Cash flow from operating activities amounted to -13.3 MSEK (-10.7 MSEK)

Business operations for sale

- Profit after tax amounted to -1.6 MSEK

The period January–December 2023

Remaining business operations

- Net sales 0.0 MSEK (5.9 MSEK)

- Other income 0.2 MSEK (0.7 MSEK)

- R&D costs for the period amounted to 4.5 MSEK (51.4 MSEK)

- Profit after tax amounted to -18.4 MSEK (-63.8 MSEK)

- Earnings per share for the period amounted to -0.18 SEK (-1.10 SEK)

- Cash flow from operating activities amounted to -15.4 MSEK (-49.8 MSEK)

Business operations for sale

- Profit after tax amounted to -17.4 MSEK

- Earnings per share for the quarter amounted to -0.17 SEK